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ABSTRACT
The present investigation reports the design and evaluation of six-hour extended release film-coated matrix tablets 
of cephalexin using different grades of hydrophilic polymer hydroxypropylmethylcellulose (HPMC) employing  direct 
compression method. The preformulation studies performed included the physical compatibility studies, Differential 
Scanning Calorimetry analysis, drug characterization using Fourier Transform Infra Red spectroscopic analysis 
and particle size analysis using sieve method. The tablets were evaluated for weight variation, hardness, thickness 
and friability. Results of the studies indicate that the polymers used have significant release-retarding effect on the 
formulation. The dissolution profile comparison of the prepared batches P1 to P8 and market preparation (Sporidex 
AF 375) was done by using Food and Drug Administration-recommended similarity factor (f2) determination. The 
formulation P8 (10% HPMC K4M, 15% HPMC 15cps) with a similarity factor (f2) of 77.75 was selected as the 
optimized formulae for scale-up batches. The dissolution data of the best formulation P8 was fitted into zero order, 
first order, Higuchi and Korsemeyer-Peppas models to identify the pharmacokinetics and mechanism of drug 
release. The results of the accelerated stability study of best formulation P8 for three months revealed that storage 
conditions were not found to have made any significant changes in final formulation F3. The release of cephalexin 
was prolonged for 6 h by using polymer combinations of HPMC and a twice daily matrix tablet was formulated.
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of drug delivery due to the ease of administration, patient 
compliance and flexibility in formulation. Extended-release 
oral drug formulations have been used since the 1960s to 
enhance performance and increase patient compliance.[1] 
By incorporating the dose for 24 h into one tablet from 
which the drug is slowly released, peaks of high plasma 
concentration and troughs of low plasma concentration 
can be prevented.[2] This helps to avoid the side-effects 
associated with high concentrations and the lack of 
activity associated with low concentrations giving better 
overall therapy. In biopharmaceutics, scientists generally 4   Journal of Young Pharmacists Vol 4 / No 1
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are faced with an engineering problem; to develop drug 
delivery systems that hit a desired target. The target 
in pharmacokinetics is generally a plasma/blood drug 
concentration that lies between the minimum effect 
concentration (MEC) and minimum toxic concentration 
(MTC). Cephalexin is a semisynthetic antibiotic derived 
from cephalosporin C and is almost completely absorbed 
from the gastrointestinal tract with a bioavailability of 95%. 
Cephalexin has a half life of around 1.1 h.[3-5] To maintain 
the therapeutic range, the drug should be administered 
three to four times a day, which leads to saw tooth kinetics 
resulting in ineffective therapy.[6] Addressing this problem, 
we attempted to formulate extended-release tablets of 
cephalexin, which can provide a constant effective drug 
level for six hours, based on calculations considering 
pharmacokinetic parameters.
MATERIALS AND METHODS
Materials
The chemicals used in the experiment are: Cephalexin 
monohydrate (Aurobindo Pharma Ltd., India), 
microcrystalline  cellulose  PH102  (Weiming 
Industries, China), lactose anhydrous (DMV- Fonterra 
Excipients, Germany), HPMC 15cps, HPMC K4M, HPMC 
K15M, HPMC K100M (Feicheng Ruitai Fine chemicals, 
China), colloidal silicon dioxide (Degussa India Pvt. Ltd., 
India), magnesium stearate (Ferro Corporation, USA), 
Instacoat universal (Ideal Curves Pvt. Ltd., India), Sporidex 
AF 375 (Ranbaxy laboratories Pvt. Ltd., India). All the other 
reagents used were of analytical grade.
Methods
Preformulation studies
Preformulation investigations are done to characterize 
properties of raw materials including their physico-
chemical, biopharmaceutical, and mechanical properties, 
as well as compatibility.
Physical drug excipient compatibility studies
The physical compatibility studies were coupled with 
the stability studies at higher temperature and humidity 
conditions. The drug excipient compatibility study protocol 
included the preparation of homogenous physical mixture in 
1:1 ratio of drug and all possible excipients to be used in the 
formulation. The physical mixtures were sealed into 15-ml 
USP Type III flint glass vials and stored in a stability chamber 
(Servewell instruments Pvt. Ltd., Bengaluru, India) for 30 days 
at 40°C temperature and 75% relative humidity conditions. 
The initial state of the mixtures was noted and further 
evaluation for the possible occurrence of any interactions 
like physical or chemical changes, was performed after the 
15th and 30th day.[7,8] 
Differential scanning calorimetry
The DSC thermograms of pure drug, polymer and 
formulation were generated and investigated for presence 
of additional peaks or absence of peaks indicating possible 
polymer interactions or phase transformations. The 
thermal peaks give the melting points of the samples which 
can be used as a test for purity analysis and also for sample 
characterization by comparing with the standard melting 
points reported for corresponding samples.[7-9]
Drug characterization using FTIR spectroscopy
The authenticity of the drug cephalexin monohydrate 
was confirmed by comparing the absorption maxima with 
that of cephalexin monohydrate reference standard. The 
KBr pellet method was used to generate the IR spectrum 
(Shimadzu Corporation, Japan) of the raw material and 
the reference standard and spectrum was compared for 
identification and purity analysis of the sample. The 
overlaid spectrum confirms the authenticity of the raw 
material and is provided in Figure 1.[7,9]
Particle size analysis of  drug
Active pharmaceutical ingredient (API) [cephalexin 
monohydrate] was analyzed for particle size distribution 
by means of sieving method using mechanical sieve shaker 
(Verder RETSCH Trading co. Ltd, China). A series of 
standard sieves namely 30#, 40#, 60#, 80# and 100# were 
stacked one above the other so that sieves with larger pore 
size (less sieve number) occupied top position followed by 
sieves of decreasing pore size (larger sieve number) towards 
the bottom. Weighed quantity of API was placed in sieve no. 
40. Sieve shaker was set for 5 min at amplitude of 60. Remove 
Figure 1: FTIR spectrum combined of cephalexin sample and 
cephalexin RS. The red spectrum and blue spectrum are of cephalexin 
RS and cephalexin sample respectivelyJournal of Young Pharmacists Vol 4 / No 1  5
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the set up from the sieve shaker after 5 min and weigh the API 
retained in each mesh individually. The percentage retained 
in each sieve was calculated with the following formula.[9]
Percentr etained
Mass retained on eachsieve
Total weighto fs ample
=× ×100
Determination of dosage for cephalexin extended-
release tablets
Determination of the total dose required for a sustained 
release dosage form, requires the addition of the amount of 
drug needed to achieve the desired blood level quickly (the 
immediately available portion) to the sustaining portion.
DT = DI* + DM 
Where,
DT, DI* and DM are total dose of drug required, corrected 
initial dose and maintenance dose/sustained dose respectively.
The sustaining portion is determined by multiplying the 
zero-order rate constant for sustained drug delivery, KR
0, 
by the desired sustaining time, h. The desired zero order 
release rate is determined by the equation below;
KR
0 = KE * Vd * DTC
Where,
KR
0, KE, Vd and DTC are zero-order rate constant, first 
order elimination rate constant, volume of distribution 
and desired therapeutic concentration respectively. KE can 
be determined by the equation;
KE = 0.693/t1/2
The maintenance dose is calculated using the equation 
below
DM = KR
0 * T
Where ‘T’ is desired duration of extended release. Amount 
of drug released from maintenance dose during release of 
initial dose till peak plasma concentration (cmax) is calculated 
using the equation given below;
W = KR
0 * Tmax
Where,
W and Tmax are amount of drug released from maintenance 
dose during release of initial dose till peak plasma 
concentration Cmax and time to reach Cmax respectively.
The corrected initial dose is calculated using the equation 
given below;[10]
DI* = DI – W
Where DI is the initial dose.
Determination of amount of cephalexin to be used 
in a tablet
Cephalexin is available as a hydrous molecule cephalexin 
monohydrate. Labeled claims are to be expressed in terms 
of the equivalent amount of anhydrous cephalexin present 
in the dosage form. The quality control department 
analyses the raw material and determines the assay value 
and percentage of water present in it. These variables can 
be used to determine the conversion factor, a term which 
decides the actual amount of cephalexin monohydrate to 
be used in order to meet the labeled claim specification of 
cephalexin present on anhydrous basis. The total amount of 
cephalexin to be used in the formulation can be calculated 
using the following formula:
Required dose = Labeled claim × Conversion factor
Conversion factor =     100   ×   100         
      (%w/w assay on anhydrous basis) 
      (100% w/w water by KF)
Formulation of cephalexin matrix tablets using direct 
compression method
Manufacture of matrix tablets by direct compression 
method involves mainly three steps.
1.  Sifting: Accurately weighed quantity of drug and 
excipients were passed through sieve no. 20 and 40 
respectively.
2.  Blending: Drug and excipients (excluding lubricant) 
were added in geometric proportions and mixed 
thoroughly for 15 min.
3.  Compression: The blend was mixed slightly with 
lubricant and finally compressed in 15 * 8.5 mm 
punches.
Total of eight batches (P1 to P8) were prepared and 
the formulae used are represented in Table 1. The pre-
compression parameters of cephalexin granules like angle 
of repose, bulk density, tapped density, Carr’s index and 
Hausner’s ratio are summarized in Table 2. The prepared 
cephalexin matrix tablets were evaluated for thickness, 
hardness, friability, uniformity of weight and drug content. 
The thicknesses of tablets were measured by vernier 
caliper (Aerospace, China). Hardness of tablets was 6   Journal of Young Pharmacists Vol 4 / No 1
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tested using a validated modified dial type hardness tester 
(Shivani Scientific Industries, India). Friability of tablets 
was determined by using Roche Friabilator (Electrolabs, 
India). The drug content of each batch was determined 
as per USP assay of cephalexin using HPLC (SCL-10AVP, 
Shimadzu Corporation, Japan).[10,11] The tablet evaluation 
results are summarized in Table 3.
In vitro drug release study
Preparation of  buffers and reagents
Preparation of 0.01N HCl: 8.5 ml of concentrated 
hydrochloric acid was accurately measured and diluted to 
10 liter with demineralized water to obtain 0.01N HCl.[9]
Preparation of 0.2M mono basic potassium phosphate: 
About 27.22  g of mono basic potassium phosphate 
(KH2PO4) was dissolved and diluted to 1000 ml with 
demineralized water.[9]
Preparation of 0.2M sodium hydroxide solution: About 
8.0 g of sodium hydroxide (NaOH) was dissolved and 
diluted to 1000 ml with demineralized water.[9]
Preparation of phosphate buffer (pH=6.8): 250 ml of 
mono basic potassium phosphate (KH2PO4) was placed in a 
1000 ml volumetric flask, 112 ml of 0.2M NaOH was added 
and volume was made up to 1000 ml with demineralized 
water and pH adjusted to 6.8 using dilute NaOH solution.[9]
Procedure of dissolution study: The in vitro dissolution 
studies of cephalexin extended-release tablets were 
performed using USP Type I dissolution apparatus 
(basket type) (Electrolabs, India). The dissolution medium 
consisted of 900 ml of 0.01N HCl (1st h) and phosphate 
buffer (pH=6.8) during the rest of the study period 
maintained at 37±0.2°C. The speed of the paddle was set 
at 100 rpm. Aliquot of samples (5 ml) were withdrawn at 
specific time intervals and the same amount of buffer was 
Table 1: Composition of batches P1 to P8
Ingredients P1 P2 P3 P4 P5 P6 P7 P8
Cephalexin monohydrate 401.25 401.25 401.25 401.25 401.25 401.25 401.25 401.25
(MCC PH102) 126.75 66.75 66.75 66.75 6.75 6.75 36.75
Lactose anhydrous 126.75
HPMC K4M 60.00 60.00 60.00 60.00 60.00
HPMC K15M 60.00 60.00
HPMC K100M 60.00
HPMC K15cps 60.00 60.00 60.00 120.00 120.00 90.00
Colloidal silicon dioxide 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00
Magnesium stearate 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00
Average tablet weight 600.00 600.00 600.00 600.00 600.00 600.00 600.00 600.00
Table 2: Precompression parameters of batches P1 to P8
Formulation Angle of repose (q)* Bulk density (g/cm3) Tapped density (g/cm3) Carr’s index (%) Hausner’s ratio
P1 33°44’±1.12 0.575 0.708 18.78 1.23
P2 36°27± 0.63 0.521 0.671 22.35 1.28
P3 35°18’±0.54 0.552 0.682 19.06 1.23
P4 34°28’±0.37 0.534 0.664 19.57 1.24
P5 34°19’±0.58 0.561 0.693 19.04 1.23
P6 35°48’±0.85 0.578 0.732 21.03 1.26
P7 34°39’±0.28 0.533 0.648 17.78 1.21
P8 35°12’±0.44 0.525 0.726 18.56 1.22
*The values are expressed as mean ± SD; n=3
Table 3: Post-compression parameters of batches P1 to P8
Formulation Weight variation (%)* Thickness (mm)* Hardness (kg/cm2)* Friability (%)** Drug content (%)
P1 1.12 ± 2.37 5.28 ± 0.04 14.63 ± 0.81 0.05 ± 0.16 96.45 
P2 2.56 ± 3.15 5.31 ± 0.03 14.52 ± 1.36 0.02 ± 0.25 92.18
P3 2.08 ± 1.83 5.36 ± 0.04 12.74 ± 1.29 0.03 ± 0.28 95.34
P4 2.72 ± 3.63 5.28 ± 0.03 12.16 ± 1.27 0.05 ± 0.53 92.56
P5 1.86 ± 4.63 5.34 ± 0.04 12.25 ± 1.46 0.04 ± 0.65 94.17
P6 2.53 ± 3.12 5.39 ± 0.04 12.33 ± 1.54 0.06 ± 0.33 92.49
P7 1.75 ± 2.79 5.29 ± 0.05 13.64 ± 0.92 0.03 ± 0.57 95.13 
P8 2.13 ± 3.15 5.16 ± 0.06 12.12 ± 0.37 0.05 ± 0.46 97.51
*Values are expressed as mean±SD; n=20; **Values are expressed as mean±SD; n=3Journal of Young Pharmacists Vol 4 / No 1  7
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replaced into the dissolution bowl to maintain the sink 
conditions.[9]
Preparation of cephalexin standard stock solution (200 µg/
ml): A standard stock solution of cephalexin monohydrate 
was prepared by dissolving accurately weighed 20 mg of 
cephalexin reference standard in corresponding medium 
(0.01N HCl and phosphate buffer) and made up to volume 
in a 100 ml standard flask. Ten ml of the above solution 
was again diluted to 100 ml in a standard flask to get a 
solution of concentration 20 µg/ml which is used as the 
cephalexin working standard.[9]
Estimation of drug release using single external standard 
method: Five ml of sample withdrawn was diluted with 
corresponding medium and made up to volume in a 100 
ml standard flask. The above solution was sonicated for 
15 min and the absorbance was measured at 262 nm. The 
amount of cephalexin release was determined in a UV-
1650 spectrophotometer (Shimadzu corp., Japan) at the 
wavelength of maximum absorbance 262 nm using the 
formula below:
%Drug release =
wt.ofstd.*sampleabs.*sampledilution
* potencyo ofstd.
std.dilution *std.absorbance
*l abelclaim
The in vitro drug release specification was 20-40% at 
1st h, 40-60% at 2nd h, 60-80% at 4th h and > 80% at 6th h 
determined from theoretical drug release and dissolution 
pattern of the marketed product. The in vitro drug release 
data is summarized in Table 4 and graphically represented 
in Figure 2.
Estimation of drug content using high-performance 
liquid chromatography
The assay of cephalexin by high-performance liquid 
chromatography (HPLC) was performed as per USP 
procedure. The procedure involves preparation of mobile 
phase, internal standard solution, standard and sample.
Preparation of  mobile phase
1015 ml of a suitable mixture of water:acetonitrile:methanol: 
triethylamine (850:100:50:15) was prepared. One gram 
sodium 1-pentanesulfonate was dissolved in this mixture; 
adjusted with phosphoric acid to a pH of 3.0 ± 0.1 and 
degassed.[12]
Preparation of  standard
Dissolved an accurately weighed quantity 20 mg of USP 
cephalexin reference standard with water in a 100 ml 
standard flask. The solution was sonicated and filtered to 
obtain the standard solution.
Assay preparation and procedure
Twenty tablets were weighed and finely powdered. An 
accurately weighed quantity of powder equivalent to 20 mg 
of cephalexin was transferred to a 100 ml of volumetric 
flask; water was added to the volume and mixed. The 
solution was sonicated and filtered to obtain a clear 
solution. Equal volumes (20 µl) of standard (five times) and 
assay samples (two times) were injected separately into the 
chromatographs and corresponding chromatograms were 
recorded and the responses for major peaks were noted. 
Figure 2: Cumulative percentage drug release of P1 to P8 (graphical 
representation)
Table 4: Cumulative percentage drug release of P1 to P8
Formulation code Cumulative percentage drug release*
1st h 2nd h 4th h 6th h
P1 62.86 ± 1.16 78.36 ± 0.73 96.61 ± 1.34 95.04 ± 0.92
P2 65.16 ± 1.99 77.13 ± 1.56 93.86 ± 1.82 95.02 ± 1.95
P3 54.43 ± 1.35 65.33 ± 0.93 74.70 ± 1.03 97.98 ± 0.78
P4 52.19 ± 1.43 62.39 ± 1.49 71.93 ± 1.24 100.82 ± 1.05
P5 37.25 ± 0.78 45.32 ± 0.86 54.38 ± 1.17 69.16 ± 1.27
P6 20.75 ± 1.19 37.83 ± 0.97 71.67 ± 0.77 91.97 ± 0.74
P7 20.91 ± 0.50 35.08 ± 0.82 64.90 ± 0.49 89.47 ± 0.95
P8 31.14 ± 0.22 53.67 ± 1.36 78.13 ± 0.12 93.42 ± 0.31
'*' Values are expressed as mean ± SD; n=68   Journal of Young Pharmacists Vol 4 / No 1
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The program gives the mean standard and sample peak 
areas, which when substituted in the formula below gives 
the %w/w of cephalexin present in the sample assayed.[12] 
The drug content values are indicated in Table 3:
%D rugc ontent =
wt.ofstd.*meansamplearea.*
potencyofstd. * fil ll wt.
wt.ofsample *m eanstd.area*
labelclaim
Comparison of dissolution profiles
The similarity in the drug release pattern of the marketed 
product and the formulation developed was determined 
by calculating the similarity factor (f2). The two products 
are said to be similar if the value of f2  lies between 50 
and 100. The similarity factor and a similarity testing have 
been recommended for dissolution profile comparison in 
the Food and Drug Administration (FDA)’s Guidance for 
Industry. f2 is given by the formula given below:
f R- T tt 2
2
1 05
50 11 100 =+









 



 
= −
∑ log/ () *
.
n
t
n
Where,
Rt = percentage of reference product dissolved at a 
specified time
Tt = percentage of test product dissolved at a specified time.
n = no: of sampling points.
The similarity factors of batches P1 to P8 are shown in 
Table 5. The formulation P8 was found to have a similarity 
factor of 77.75 and was chosen to be the scale up batch 
formulae. The drug release pattern of optimized product 
P8 and the theoretical release pattern were compared to 
determine the similarity represented by Figure 3. The graph 
shows good correlation between the dissolution profiles of 
marketed product, F3 and the theoretical release pattern.[13]
Kinetic modeling of in vitro drug release
To study the release kinetics, the data obtained from in vitro 
drug release studies of optimized formulation P8 was 
plotted in various kinetic models:
1.  Zero order rate kinetics: Cumulative percentage of drug 
released vs. time
2.  First order rate kinetics: Log cumulative percentage of 
drug remaining vs. time
3.  Higuchi model : Cumulative percentage of drug released 
vs. square root of time
Table 5: Similarity factor of formulation P1 to P8
Formulations Similarity factor (f2)
P1 19.43
P2 19.88
P3 34.23
P4 37.10
P5 32.34
P6 41.92
P7 36.69
P8* 77.75
*The batch had the highest f2 and the formulae was used for the scale up batches 
Figure 3: Comparative dissolution profiles of marketed product 
(Sporidex 375), P8 and theoretical release profile.
4.  Korsmeyer Peppas model: Log cumulative percentage 
of drug released vs. log time
The plots were drawn using Microsoft Excel 2007 and 
the regression equations were obtained for each plot. 
The linearity of the plots was obtained from the value 
of regression coefficient (R). The model with the highest 
linearity (R value approaches unity) was chosen as the best-
fit kinetic model. The Korsmeyer Peppas model is used to 
study the mechanism of drug and the slope of the plots 
gives the diffusional exponent ‘n’. When n<0.5, the drug 
diffuses through the polymeric matrix by a Fickian (Case I) 
diffusion mechanism. For 0.5<n<1, an anomalous (non-
Fickian) mechanism occurs; n=1 indicates a zero-order 
(Case II) and n>1 indicates non-Fickian super Case II 
release mechanism.[13,14]
Film coating of tablets
Coating specifications
Coating technique  : Pan coating
Inlet temperature  : 50°C-78°C
Pan speed  : 2-6 rpm
Pump speed  : 10-20 rpm
Atomization pressure  : 1.5-3.5 kg/cmJournal of Young Pharmacists Vol 4 / No 1  9
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Preparation of  coating solution
The compressed tablets were film-coated with Instacoat 
universal by using conventional coating pan (Jyothi 
Industries, Bengaluru). The amount of Instacoat required is 
about 3% of the weight of the tablet bulk to be coated and 
this amount forms 5% of the total reconstituted coating 
solution. The solvent system for reconstitution consists 
of IPA:MC in the ratio 35:65. The coating solution was 
prepared by dispersing specified quantity of Instacoat in 
isopropyl alcohol and stirred for 5  min. Then accurate 
quantity of methylene chloride was added and stirring 
was continued until a clear dispersion was formed. The 
targeted weight gain of the tablets after coating was fixed 
to be 2.5%.[10]
Fourier transform infra red study
FTIR studies were used to study the interaction between 
the drug and excipients. The scanning was done from 
4000 cm-1 to 400  cm-1. The spectral data of cephalexin 
standard and formulation P8 was interpreted in detail and 
the overlaid spectrum [Figure 4] shows similar peaks and the 
signal assignment is provided in Table 6 to give substantial 
evidence in support of chemical and physical compatibility 
between the drug and excipients used in the formulation.[9]
Accelerated stability studies
Short-term accelerated stability studies for a period of 
three months according to International Conference 
on Harmonization guidelines were performed on the 
optimized tablet formulations of blister-packed cephalexin 
extended-release tablets. The tablets were subjected to 
stability studies at 40°C/75%RH in a stability chamber for 
a period of three months. Initial evaluation of the tablets 
was done and at the end of first, second and third month 
the tablets were again analyzed for physical appearance, 
water content and in vitro drug release profile.[15]
RESULTS AND DISCUSSION
Physical drug excipient compatibility studies
From the drug excipients’ compatibility study report 
shown in Table 7, it was observed that there were 
no incompatibilities or interaction between drug 
and excipients. Based on the physical compatibility 
result, the excipients were chosen for the formulation 
development.
Differential scanning calorimetry
The drug shows an exothermic peak at 190.72°C 
[Figure 5] and polymer HPMC 15cps shows a broad 
endothermic transition peak at 81.33°C [Figure 6]. The 
DSC thermogram of formulation P8 [Figure 7] shows 
an exothermic peak at 188.95°C (drug) and endothermic 
peak at 92.19°C (polymer) thus retaining the peak of 
drug and the polymer. The DSC thermograms of pure 
drug, polymer and formulation (P8) reveal that polymer 
interactions or phase transformations have not occurred 
and the drug and excipients are chemically compatible 
with each other.
Particle size analysis of drug
Initial weight of powder: 50 g
Final weight of powder: 49.23 g
From the sieve analysis report shown in Table 8, it was 
concluded that 78% of the drug particles had a size less 
than 150 µm and as no powder was retained on sieve no. 
20, it was found suitable for sifting of drug during the 
formulation development.
Table 6: Spectral interpretation of cephalexin RS and P8
Wave no. in cm−1 Signal assignment
3270 (moderate peak) OH group of H2O
3100.89 Aromatic C-H stretching
2850-2925 Methyne C-H stretch, methylene
C-H asymmetric stretch
2600 (moderate peak) NH3
+
1760 β lactam C=O stretch (constrained 
carbonyl group)
1686.44 Amide C=O stretch
1600 (broad peak) Carboxylate stretching (COO_)
1450 Aromatic ring stretch
1225-950 (series of peaks) Aromatic C-H in plane bending
1070 Primary amine (C-N stretch)
820-690 (series of peaks) Skeletal vibrations of aromatic ring
710-690 Mono substituted phenyl ring
690 CH2-S- (C-S stretch)
Figure 4: Combined Spectrum of cephalexin RS and P8. The red 
spectrum and green spectrum are of cephalexin RS and cephalexin 
ER 375 (P8) respectively10   Journal of Young Pharmacists Vol 4 / No 1
Vijay, et al.: Formulation and evaluation of cephalexin extended-release matrix tablets
Figure 5: DSC thermogram of cephalexin
Figure 6: DSC thermogram of HPMC 15cps
Figure 7: DSC thermogram of P8
Table 7: Drug excipient compatibility report
Composition Description
Initial 2 weeks 4 weeks
Cephalexin White to off  
white powder
No color  
change
No color   
change
Cephalexin + microcrystalline 
cellulose
White to off  
white powder
No color  
change
No color   
change
Cephalexin + lactose White to off  
white powder
No color 
change
No color   
change
Cephalexin + HPMC15cps White to off  
white powder
No color  
change
No color   
change
Cephalexin + HPMC K4M White to off  
white powder
No color  
change
No color   
change
Cephalexin + HPMC K100M White to off  
white powder
No color  
change
No color   
change
Cephalexin + HPMC K15M White to off  
white powder
No color  
change
No color   
change
Cephalexin + colloidal silicon 
dioxide
White to off  
white powder
No color 
change
No color   
change
Cephalexin + magnesium 
stearate
White to off  
white powder
No color  
change
No color   
change
Determination of dosage for cephalexin extended-
release tablets
The plasma half life (t1/2) of cephalexin was reported to be 
around 1 h and the volume of distribution (Vd) was almost 
15 liters. For 125 mg dose the desired therapeutic concentration 
obtained was 4.5  mg/l. The drug release was sustained for 
duration of 6 h. Thus the desired zero order release rate is;
KR
0 = 0.693  * 15  * 4.5
  = 46.7 mg/h
The maintenance dose was calculated and is;
DM = 46.7* 6
  = 280.7 mg
The Tmax of cephalexin was reported to be 1 h. Amount of 
drug released from maintenance dose during release of initial 
dose till peak plasma concentration (cmax) was calculated to be:
W = 46.7 * 1
  = 46.7 mg
The corrected initial dose was calculated to be:
DI* = 125 – 46.7
  = 78.3 mg
So the total dose becomes;
DT = 78.3 + 280.7
  = 359 mg
The corrected dose of cephalexin taken was 375 mg for 
the preparation of matrix tablets.
Determination of amount of cephalexin to be used 
in a tablet
The quantity of cephalexin monohydrate to be used in the 
formulation of a tablet containing 375 mg of cephalexin 
anhydrous was calculated from the assay value and the water 
content determined by the Karl-Fischer method.Journal of Young Pharmacists Vol 4 / No 1  11
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Table 8: Particle size distribution of cephalexin
Sieve no. Aperture size (mm) Sample retained on each sieve(g) % of sample retained Cumulative % retained
20 0.850 0.00 0.00 0.00
30 0.650 1.46 2.85 2.85
40 0.425 10.62 21.24 24.09
60 0.250 11.01 22.02 46.11
80 0.180 15.47 30.95 77.06
100 0.150 0.25 0.49 77.55
Collector pan - 10.45 20.90 98.45
Total - 49.23 98.45 -
Table 9: Kinetic study report of P8
Code Kinetic model
Zero order First order Korsemeyer Higuchi
R2 K0 R2 K1 R2 n R2 KH
P8 0.957 12.09 0.985 0.46 0.942 0.32 0.991 42.73
Period: One month. Study conditions: 40°C/75%RH
Table 10: Accelerated stability studies report of cephalexin ER 375 (P8)
Period Dissolution (%) Assay (%) Appearance
1st h 2nd h 3rd h 4th h
Initial 31.14  53.67 78.13 93.42 94.85 Off white color
1st month 32.45 47.844 72.64 95.12 97.24 Off white color
2nd month 33.18 50.12 74.38 94.38 96.36 Off white color
3rd month 32.54 53.46 71.69 96.51 95.89 Off white color
Assay value = 100.36%
%Water content = 6.55%
Correction factor=1.07; the required amount of cephalexin 
monohydrate was calculated using Equation 8 and was 
found to be 401.25 mg.
Kinetic modeling of in vitro drug release
The kinetic study reveals that the cephalexin extended-
release tablets follow mixed order kinetics as the 
regression coefficients approach unity for first and zero 
orders. The n values from the Korsemeyer Peppas model 
show that the drug release pattern follows mainly the 
Fickian diffusion mechanism as the n value is below 0.5. 
The Higuchi plots also show good linearity indicating that 
the drug release is proportional to the square root of time 
and the drug release is at a slower rate as the distance 
of diffusion increases. The results are summarized in 
Table 9.
Accelerated stability studies report
The accelerated stability studies for three months as per 
ICH guidelines reveal that the formulation (P8) has not 
undergone any physical or chemical degradation during 
the period. There are no significant differences in the 
in vitro drug release and the drug content of the optimized 
formulation [Table 10].
CONCLUSION
The present research work was successful in improving 
the efficacy of cephalexin oral therapy as the drug release 
was extended for six hours thus reducing dosing frequency 
thereby improving patient compliance. The saw tooth 
kinetics of conventional therapy was completely avoided 
by the development of a new formulation. The study 
also revealed the applicability of different grades of 
hydroxypropylmethylcellulose as rate-controlling polymers 
in matrix tablets. The mixed polymer combination of 
grades HPMC K4M and HPMC 15cps was found to 
sustain the release of cephalexin for six hours and also 
met the release specifications. The higher viscosity grades 
of HPMC were not found suitable for small duration of 
sustained drug release t. The in vitro drug release profile of 
the newly developed tablets also shows good similarity with 
that of the innovator’s product and ideal controlled release 
pattern. There were no formulation problems associated 
with the optimized batch (P8) of cephalexin matrix tablets. 
The tablet also passed the short-term accelerated stability 
studies indicating the physical and chemical stability of 
the product.12   Journal of Young Pharmacists Vol 4 / No 1
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